Compile Data Set for Download or QSAR
Report error Found 160 Enz. Inhib. hit(s) with all data for entry = 6944
TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160781(US9045524, 48 | US10167313, Compound 48)
Affinity DataIC50: 10nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160788(US9045524, 55 | US10167313, Compound 55)
Affinity DataIC50: 10nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160798(US9045524, 65 | US10167313, Compound 65)
Affinity DataIC50: 10nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160792(US9045524, 59 | US10167313, Compound 59)
Affinity DataIC50: 20nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160816(US9045524, 85 | US10167313, Compound 85)
Affinity DataIC50: 30nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160808(US9045524, 76 | US10167313, Compound 76)
Affinity DataIC50: 30nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160790(US9045524, 57 | US10167313, Compound 57)
Affinity DataIC50: 30nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-7(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160792(US9045524, 59 | US10167313, Compound 59)
Affinity DataIC50: 40nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160796(US9045524, 63 | US10167313, Compound 63)
Affinity DataIC50: 40nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160819(US9045524, 88 | US10167313, Compound 88)
Affinity DataIC50: 40nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160849(US9045524, 123)
Affinity DataIC50: 60nMAssay Description:The inhibition of the activity of Caspase-1 to -10 by four different compounds (#53, #111, #123 & Z-DEVD-FMK used as a prodrug: z-D(OMe)E(OMe)VD(OMe)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160786(US9045524, 53 | US10167313, Compound 53)
Affinity DataIC50: 60nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160841(US9045524, 111)
Affinity DataIC50: 80nMAssay Description:The inhibition of the activity of Caspase-1 to -10 by four different compounds (#53, #111, #123 & Z-DEVD-FMK used as a prodrug: z-D(OMe)E(OMe)VD(OMe)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160786(US9045524, 53 | US10167313, Compound 53)
Affinity DataIC50: 90nMAssay Description:The inhibition of the activity of Caspase-1 to -10 by four different compounds (#53, #111, #123 & Z-DEVD-FMK used as a prodrug: z-D(OMe)E(OMe)VD(OMe)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160804(US9045524, 71)
Affinity DataIC50: 100nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160802(US9045524, 69 | US10167313, Compound 69)
Affinity DataIC50: 100nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-7(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160790(US9045524, 57 | US10167313, Compound 57)
Affinity DataIC50: 200nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160799(US9045524, 66 | US10167313, Compound 66)
Affinity DataIC50: 200nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160801(US9045524, 68 | US10167313, Compound 68)
Affinity DataIC50: 200nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-9(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160798(US9045524, 65 | US10167313, Compound 65)
Affinity DataIC50: 300nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160803(US9045524, 70)
Affinity DataIC50: 300nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160813(US9045524, 82 | US10167313, Compound 82)
Affinity DataIC50: 300nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-7(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160781(US9045524, 48 | US10167313, Compound 48)
Affinity DataIC50: 400nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-7(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160798(US9045524, 65 | US10167313, Compound 65)
Affinity DataIC50: 400nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-7(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160849(US9045524, 123)
Affinity DataIC50: 500nMAssay Description:The inhibition of the activity of Caspase-1 to -10 by four different compounds (#53, #111, #123 & Z-DEVD-FMK used as a prodrug: z-D(OMe)E(OMe)VD(OMe)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-1(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160813(US9045524, 82 | US10167313, Compound 82)
Affinity DataIC50: 500nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-9(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160792(US9045524, 59 | US10167313, Compound 59)
Affinity DataIC50: 500nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-1(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160819(US9045524, 88 | US10167313, Compound 88)
Affinity DataIC50: 700nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-7(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160808(US9045524, 76 | US10167313, Compound 76)
Affinity DataIC50: 700nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-7(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160786(US9045524, 53 | US10167313, Compound 53)
Affinity DataIC50: 800nMAssay Description:The inhibition of the activity of Caspase-1 to -10 by four different compounds (#53, #111, #123 & Z-DEVD-FMK used as a prodrug: z-D(OMe)E(OMe)VD(OMe)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-7(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160786(US9045524, 53 | US10167313, Compound 53)
Affinity DataIC50: 800nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-1(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160790(US9045524, 57 | US10167313, Compound 57)
Affinity DataIC50: 900nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-7(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160816(US9045524, 85 | US10167313, Compound 85)
Affinity DataIC50: 1.00E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160784(US9045524, 51 | US10167313, Compound 51)
Affinity DataIC50: 1.00E+3nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-7(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160819(US9045524, 88 | US10167313, Compound 88)
Affinity DataIC50: 1.10E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-1(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160798(US9045524, 65 | US10167313, Compound 65)
Affinity DataIC50: 1.20E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-9(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160781(US9045524, 48 | US10167313, Compound 48)
Affinity DataIC50: 1.20E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-1(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160827(US9045524, 96 | US10167313, Compound 96)
Affinity DataIC50: 1.30E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-1(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160792(US9045524, 59 | US10167313, Compound 59)
Affinity DataIC50: 1.40E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-7(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160788(US9045524, 55 | US10167313, Compound 55)
Affinity DataIC50: 1.40E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-7(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160801(US9045524, 68 | US10167313, Compound 68)
Affinity DataIC50: 1.50E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-9(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160813(US9045524, 82 | US10167313, Compound 82)
Affinity DataIC50: 1.60E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-7(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160796(US9045524, 63 | US10167313, Compound 63)
Affinity DataIC50: 1.80E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-7(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160802(US9045524, 69 | US10167313, Compound 69)
Affinity DataIC50: 1.80E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-10(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160849(US9045524, 123)
Affinity DataIC50: 2.00E+3nMAssay Description:The inhibition of the activity of Caspase-1 to -10 by four different compounds (#53, #111, #123 & Z-DEVD-FMK used as a prodrug: z-D(OMe)E(OMe)VD(OMe)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-1(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160786(US9045524, 53 | US10167313, Compound 53)
Affinity DataIC50: 2.00E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160769(US9045524, 36 | US10167313, Compound 36)
Affinity DataIC50: 2.00E+3nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160770(US9045524, 37 | US10167313, Compound 37)
Affinity DataIC50: 2.00E+3nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-3(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160750(US9045524, 16 | US10167313, Compound 16)
Affinity DataIC50: 2.00E+3nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetCaspase-1(Human)
Novagenesis Foundation

US Patent
LigandPNGBDBM160786(US9045524, 53 | US10167313, Compound 53)
Affinity DataIC50: 2.10E+3nMAssay Description:The inhibition of the activity of Caspase-1 to -10 by four different compounds (#53, #111, #123 & Z-DEVD-FMK used as a prodrug: z-D(OMe)E(OMe)VD(OMe)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

Displayed 1 to 50 (of 160 total ) | Next | Last >>
Jump to: